Project summary

Following the COVID-19 pandemic, an increasing number of individuals have been experiencing the effects of long COVID. While the understanding of long COVID remains limited, it is thought that an underlying inflammation may play a significant role in driving the disease. Unfortunately, the absence of a definitive diagnostic test for long COVID has resulted in limited access to appropriate treatment and resources for patients. Consequently, many individuals suffering from long COVID feel neglected and ignored. Nanotechnology presents a promising avenue for developing advanced diagnostic systems capable of conducting highly sensitive and multiplex analysis of various circulating biomarkers, including those associated with inflammation. This project aims to leverage digital nanotechnology, specifically the Immunostorm Chip depicted in Figure 1, to investigate the involvement of inflammatory biomarkers in patients diagnosed with long COVID. This project will provide an opportunity for students to acquire skills in a multidisciplinary environment at the interface of immunology, molecular biology and nanotechnology

Immunostorm Chip. Digitally counting of single molecules to unravel molecular drivers of long COVID. The chip is based on a nanostructured pillar array and single-particle active barcode particles that are detected by Raman microscopy. Link to the chip and an example of its application in cancer:


Project members

Professor Matt Trau

Senior Group Leader
Trau Group
ARC Australian Laureate Fellow

Dr Alain Wuethrich

NHMRC Emerging Leadership Fellow and ARC DECRA awardee
Centre for Personalised Nanomedicine (Trau Group)